MarcM.KrauseMarcM., YikangY.ZhuYikangY., MaximilianM.HuhnMaximilianM., JohannesJ.Schneider-ThomaJohannesJ., IreneI.BighelliIreneI., Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis, „European Archives of Psychiatry and Clinical Neuroscience”, 268 (7), 2018, s. 625–639, DOI:10.1007/s00406-018-0869-3, ISSN0940-1334, PMID:29368205 [dostęp 2021-12-04](ang.).
VarunV.MongaVarunV., Prasad R.P.R.PadalaPrasad R.P.R., Aripiprazole for Treatment of Apathy, „Innovations in Clinical Neuroscience”, 12 (9-10), 2015, s. 33–36, ISSN2158-8333, PMID:26634180, PMCID:PMC4655898 [dostęp 2021-12-04].
MarcM.KrauseMarcM., YikangY.ZhuYikangY., MaximilianM.HuhnMaximilianM., JohannesJ.Schneider-ThomaJohannesJ., IreneI.BighelliIreneI., Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis, „European Archives of Psychiatry and Clinical Neuroscience”, 268 (7), 2018, s. 625–639, DOI:10.1007/s00406-018-0869-3, ISSN0940-1334, PMID:29368205 [dostęp 2021-12-04](ang.).
Lindsay E.L.E.JohnsonLindsay E.L.E., LilianL.BalyanLilianL., AmyA.MagdalanyAmyA., FizzaF.SaeedFizzaF., RobertR.SalinasRobertR., The Potential for Kratom as an Antidepressant and Antipsychotic, „The Yale Journal of Biology and Medicine”, 93 (2), 2020, s. 283–289, ISSN0044-0086, PMID:32607089, PMCID:PMC7309668 [dostęp 2021-12-04].
OriO.ElisOriO., Janelle M.J.M.CaponigroJanelle M.J.M., Ann M.A.M.KringAnn M.A.M., Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions, „Clinical psychology review”, 33 (8), 2013, s. 914–928, DOI:10.1016/j.cpr.2013.07.001, ISSN0272-7358, PMID:23988452, PMCID:PMC4092118 [dostęp 2021-12-04].
VarunV.MongaVarunV., Prasad R.P.R.PadalaPrasad R.P.R., Aripiprazole for Treatment of Apathy, „Innovations in Clinical Neuroscience”, 12 (9-10), 2015, s. 33–36, ISSN2158-8333, PMID:26634180, PMCID:PMC4655898 [dostęp 2021-12-04].
MarcM.KrauseMarcM., YikangY.ZhuYikangY., MaximilianM.HuhnMaximilianM., JohannesJ.Schneider-ThomaJohannesJ., IreneI.BighelliIreneI., Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis, „European Archives of Psychiatry and Clinical Neuroscience”, 268 (7), 2018, s. 625–639, DOI:10.1007/s00406-018-0869-3, ISSN0940-1334, PMID:29368205 [dostęp 2021-12-04](ang.).
Lindsay E.L.E.JohnsonLindsay E.L.E., LilianL.BalyanLilianL., AmyA.MagdalanyAmyA., FizzaF.SaeedFizzaF., RobertR.SalinasRobertR., The Potential for Kratom as an Antidepressant and Antipsychotic, „The Yale Journal of Biology and Medicine”, 93 (2), 2020, s. 283–289, ISSN0044-0086, PMID:32607089, PMCID:PMC7309668 [dostęp 2021-12-04].
OriO.ElisOriO., Janelle M.J.M.CaponigroJanelle M.J.M., Ann M.A.M.KringAnn M.A.M., Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions, „Clinical psychology review”, 33 (8), 2013, s. 914–928, DOI:10.1016/j.cpr.2013.07.001, ISSN0272-7358, PMID:23988452, PMCID:PMC4092118 [dostęp 2021-12-04].